SABMiller’s Mackay Resumes Chairman Role After Tumor Treatment

SABMiller Plc, (SAB) the world’s second-biggest brewer, said Graham Mackay resumed his role as non-executive chairman after treatment for a brain tumor.

Mackay returned to the position yesterday after being off work since May, the London-based company said today. John Manser, who had been acting chairman, will return to his former role as deputy chairman and senior independent director.

“The directors are extremely grateful to John Manser for stepping so ably into the breach as acting chairman during my absence, and I personally have relied hugely on his support and wise counsel during what has been a very difficult few months for my family and me,” Mackay said in a statement.

In April, Mackay stepped down early as the brewer’s chief executive officer after undergoing brain surgery. As CEO, he led a slew of acquisitions, including the A$10.5 billion ($9.6 billion) takeover of Foster’s Group Ltd. in 2011. SABMiller generated $23.2 billion in revenue last year and competes with the world’s biggest brewer, Anheuser-Busch InBev NV, as well as Heineken NV and Carlsberg A/S.

Alan Clark, a company veteran of more than two decades, replaced Mackay as CEO.

“I am delighted that the transition of the chief executive’s management responsibilities to Alan Clark has gone so well,” Mackay said in today’s statement.

To contact the reporter on this story: Clementine Fletcher in London at cfletcher5@bloomberg.net

To contact the editor responsible for this story: Celeste Perri at cperri@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.